Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +584.68%
#2 Phala Phala +79.72%
#3 Bitway Bitway +36.63%
#4 ARK ARK +34.99%
#5 龙虾 (Lobster) 龙虾 (Lobster) +27.51%
#6 Backpack Backpack +26.77%
#7 The Black Bull The Black Bull +24.78%
#8 Mubarak Mubarak +24.16%
#9 APEX APEX +22.33%
#10 B3 (Base) B3 (Base) +20.43%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Настройки
Язык
Pусский
Валюта
USD
Тема
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Ранг среди акций #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Цена акции
$0.2483
Последняя синхронизация: 2026-07-31
Рыночная капитализация
$2.30M
Изменение (1 день)
-3.39%
Изменение (1 год)
-89.01%
Страна
US
Торговля Ensysce Biosciences, Inc. (ENSC)

Категория

Healthcare
История дивидендной доходности для Ensysce Biosciences, Inc. (ENSC)
Дивидендная доходность (TTM) компании Ensysce Biosciences, Inc. (тикер: ENSC) на 2023-12-31 составляет: 0.00%
Средняя дивидендная доходность за последние 5 лет: 11,707.83%
История дивидендной доходности компании Ensysce Biosciences, Inc. (ENSC) с 2017 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
2026 (TTM) 0.00% -100.00%
2024 2,039.30% 0.00%
2023 0.00% -100.00%
2022 3.76% -99.99%
2021 56,496.11% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.36%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH